Back to results
US 2026/0028346 A1Published application
Btk degrader and use thereof
AssigneesAscentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
InventorsJiantao Hu, Jianyong Chen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds that function as degraders or inhibitors of BTK. The present disclosure further relates to pharmaceutical compositions comprising them, and to their use in the treatment of diseases mediated by BTK, such as cancer.
Claims30
A compound selected from
- and pharmaceutically acceptable salts and solvates thereof.
Dependencies are inferred from the claim text.